Pediatric Diabetes Insurance Denied: CGM, Insulin Pump, and Appeal Guide

Type 1 diabetes (T1D) is a lifelong autoimmune condition that typically begins in childhood or adolescence. Unlike Type 2 diabetes, T1D requires insulin replacement and continuous management to prevent life-threatening emergencies. The American Diabetes Association's Standards of Medical Care in Diabetes set the clinical benchmark for T1D management — and when insurers deny coverage for continuous glucose monitors, insulin pumps, or other diabetes technology for children, they are often denying care that these standards explicitly support.

Continuous Glucose Monitors for Pediatric Patients

Continuous glucose monitors (CGMs) are wearable devices that measure glucose levels every few minutes and alert users to high or low blood sugar. For children with T1D, CGMs dramatically reduce hypoglycemia events, improve A1C levels, and reduce the cognitive and physical burden of diabetes management at school and during sleep.

The ADA Standards of Medical Care recommend CGMs for all children with T1D who can safely use the devices. Despite this, CGM Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization denials are common. Typical denial reasons include:

• The child does not meet the insurer's frequency-of-testing threshold (some insurers require proof of four or more daily fingerstick glucose tests)
• The specific CGM model is not on the formulary
• A less expensive CGM model is preferred
• The child is too young (some plans have age minimums, though FDA approval for some CGMs extends to age 2)

To appeal a CGM denial, your child's endocrinologist should provide a letter documenting:

• The T1D diagnosis and current management regimen
• The specific CGM recommended and why
• The child's hypoglycemia history, including any severe episodes or hypoglycemia unawareness
• Reference to ADA Standards of Medical Care, specifically the technology recommendations

The FDA has approved CGMs including the Dexcom G7, Freestyle Libre 3, and Medtronic Guardian for pediatric use. Cite the FDA-approved age range for the specific device in your appeal.

Insulin Pump Prior Authorization for Children

Insulin pumps deliver continuous subcutaneous insulin infusion (CSII) and are considered standard of care for many children with T1D, particularly those with variable schedules, frequent hypoglycemia, or high insulin sensitivity. The ADA endorses insulin pump therapy as an effective method to achieve glycemic goals in children.

Insurers typically require prior authorization for insulin pumps, with criteria that may include:

• Specific A1C thresholds (often A1C > 7.5% or evidence of frequent hypoglycemia)
• Confirmation that the child has been on multiple daily injections (MDI) for a specified period
• Completion of diabetes education
• Involvement of an endocrinologist

If your child's insulin pump prior authorization was denied, check whether the denial criteria are consistent with ADA Standards. If the insurer requires an A1C threshold that is higher than ADA's recommended target range for children (A1C < 7.0% for most pediatric patients), the criteria may be clinically inappropriate. An endocrinologist's letter challenging the prior authorization criteria as inconsistent with ADA Standards of Care is often the most effective appeal tool.

School 504 Plan Documentation and Its Role in Appeals

Children with T1D are entitled to accommodations under Section 504 of the Rehabilitation Act at any school receiving federal funding. A 504 plan documents specific diabetes management accommodations: the ability to check blood glucose at any time, access to emergency supplies, permission to eat when needed, and use of a CGM or insulin pump during the school day.

While a 504 plan is an educational accommodation document rather than a medical record, it provides supporting evidence in insurance appeals. Insurers sometimes deny CGMs by questioning whether a child's diabetes management is truly complex. A 504 plan documenting school-based glucose monitoring protocols, emergency glucagon access, and nurse involvement demonstrates the real-world complexity of managing T1D in a child's daily environment.

Closed-Loop Systems and Artificial Pancreas Technology

Automated insulin delivery (AID) systems — sometimes called artificial pancreas systems — combine a CGM with an insulin pump and a control algorithm that automatically adjusts insulin delivery. Systems such as the Tandem Control-IQ, Medtronic MiniMed 780G, and Insulet Omnipod 5 are FDA-approved for pediatric use.

AID systems are among the most advanced diabetes technology available and are increasingly standard of care for children with T1D. They are also among the most commonly denied by insurers due to their higher upfront cost.

To appeal an AID system denial, document:

• The child's hypoglycemia history and difficulty maintaining glucose in range on MDI or conventional pump therapy
• ADA Standards recommending AID systems for children with T1D
• FDA approval for the specific system in the child's age range
• The long-term cost-benefit: preventing hospitalizations for severe hypoglycemia or DKA far exceeds the device cost

Medicaid and EPSDT Coverage for Pediatric Diabetes

For children on Medicaid or CHIP, CGMs, insulin pumps, and all medically necessary diabetes supplies are covered under EPSDT (42 U.S.C. § 1396d(r)). If a Medicaid managed care organization denies diabetes technology, invoke EPSDT explicitly in your appeal and request a fair hearing.

Fight Back With ClaimBack

Children with Type 1 diabetes need their technology to survive and thrive. ClaimBack helps families navigate CGM prior authorizations, insulin pump denials, and Medicaid EPSDT claims to get children the diabetes care they need.

Start your pediatric diabetes appeal at ClaimBack

Related Reading

• What Is Medical Necessity?
• How to Write an Insurance Appeal Letter
• Common Reasons Insurance Claims Are Denied